Carmen Criscitiello
YOU?
Author Swipe
View article: Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis Open
View article: Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives
Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives Open
These results underline the willingness of patients to know more about the prospects of BM development, in contrast to the lack of routine discussion of this topic by physicians. Further investigation is warranted to demonstrate the clinic…
View article: Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis Open
Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard-of-care for hormone receptor-positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib, the first approved …
View article: Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group Open
Invasive lobular carcinoma (ILC) represents approximately 10-15% of all breast cancers and is defined by a unique discohesive morphology due to loss of E-cadherin. Despite its prevalence, ILC has been historically underrepresented in clini…
View article: Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies Open
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) improve outcomes patients affected by metastatic and early-stage hormone receptor-positive, HER2-negative breast cancer. However, approximately 20%…
View article: The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report Open
View article: Consensus document on preoperative diagnostic procedures in breast lesions
Consensus document on preoperative diagnostic procedures in breast lesions Open
In the present work, we report a comprehensive overview of breast percutaneous biopsy techniques, diagnostic categories, and multidisciplinary management based on widely acknowledged evidence of good clinical practice.
View article: Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression Open
View article: Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors Open
View article: ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy Open
Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatment with novel oral selectiv…
View article: Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment Open
View article: Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan Open
Background Metastatic triple-negative breast cancer (BC; mTNBC) is one of the most aggressive cancers, difficult to treat due to the absence of hormone target receptors. Sacituzumab govitecan (SG) is a new therapeutic approach that exploit…
View article: Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology Open
Radioligand therapy (RLT) represents a promising advancement in precision oncology and enables the targeted delivery of radiation to cancer cells. This approach has shown success in other tumor types, such as prostate cancer and neuroendoc…
View article: Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status Open
PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene ( BRCA1 v BRCA2 ) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS…
View article: Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer Open
Importance Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents is the standard first-line treatment for patients with hormone receptor–positive, ERBB2 (formerly HER2 or HER2/neu )–negative metastatic…
View article: Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer Open
View article: Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges
Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges Open
Breast cancer presents a significant risk to public health and is the primary cause of cancer‐related death in women. Awareness of metastatic breast cancer (mBC) continues to increase, and advances have been made; however, challenges remai…
View article: Analysis of Artificial Intelligence Decision-Making in Hormone Receptor-Positive / Human Epidermal Growth Factor 2-Negative Early Breast Cancer within Routine Clinical Practice and Clinical Trial
Analysis of Artificial Intelligence Decision-Making in Hormone Receptor-Positive / Human Epidermal Growth Factor 2-Negative Early Breast Cancer within Routine Clinical Practice and Clinical Trial Open
View article: Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis
Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis Open
View article: The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit Open
Background: Early-phase clinical trials offer a unique opportunity for patients with cancer. These trials often mandate biopsies to collect tumor tissue for research purposes, requiring patients to undergo invasive procedures. Some trials …
View article: Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer
Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer Open
View article: Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment Open
Breast cancer (BC) is a leading cause of death among women, with approximately 30% HER2-positive (HER2+). Although HER2-targeted therapies have improved outcomes for patients with HER2+ metastatic breast cancer (mBC), significant clinical …
View article: Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer Open
View article: Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy Open
View article: Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project Open
View article: Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations Open
ER+/HER2- mBCs carrying ESR1MUT exhibit a divergent genomic background, characterized by a lower prevalence of TP53 and MAPK pathway alterations. Less common ESR1 alterations falling outside the H11-H12 region seem to occur in t…
View article: Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 Open
View article: Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study Open
View article: Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Open
Background The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patient…
View article: Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023
Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023 Open
Importance Clinical trials are the path to test and introduce new therapies in the clinic. Trials that are unable to produce results represent inefficiency in the system and may also undermine patient confidence in the new drug development…